ABMS Announces New Board of Directors
ABMS Announces New Board of Directors

The American Board of Medical Specialties (ABMS), the leading not-for-profit organization overseeing physician certification in the United States, is pleased to announce the election of four new members to its Board of...

Allergan Receives FDA Clearance For CoolTone™ Device
Allergan Receives FDA Clearance For CoolTone™ Device

Allergan plc (NYSE: AGN) today announced CoolTone device received FDA clearance for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for...

Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and...

FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy
FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy

XW Laboratories Inc. (XW Labs), a clinical-stage biopharmaceutical company pioneering the discovery of novel small molecule therapeutics for the treatment of neurological disorders, today announced that the U.S. Food and...

touchCARDIO's Journal, Heart International, Becomes the Official Journal of C3
touchCARDIO's Journal, Heart International, Becomes the Official Journal of C3

On the first day of their 15th global summit in Orlando, C3 have confirmed that they have formed an exclusive partnership with Heart International, a leading journal from medical education provider touchCARDIO. As part of...

Clinically-Based Addiction Medicine Conference Responds to Opioid Epidemic
Clinically-Based Addiction Medicine Conference Responds to Opioid Epidemic

As the opioid epidemic continues to rage in the U.S., the need for increasing the number of qualified specialists to treat the disease of addiction has never been greater. In addition, the epidemic has also spurred the...

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b...

FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)

Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval of AMAG Pharmaceuticals, Inc.'s New Drug Application (NDA) for Vyleesi™...

Chan Zuckerberg Initiative Awards $68 Million to Support the Growth of the Human Cell Atlas
Chan Zuckerberg Initiative Awards $68 Million to Support the Growth of the Human Cell Atlas

Today, the Chan Zuckerberg Initiative (CZI) announced $68 million in funding to support the Human Cell Atlas and its selection of 38 collaborative science teams to launch CZI's Seed Networks for a Human Cell Atlas...

Brainomix® Stroke Imaging Solution Improves Consistency of Image Interpretation for Doctors
Brainomix® Stroke Imaging Solution Improves Consistency of Image Interpretation for Doctors

e-CTA®, developed by Brainomix, provides fast, consistent collateral assessments powered by AI and Deep Learning, based on CTA analysis. The recently published CATS study showed that e-CTA® provides a real-time and fully...

Mölnlycke Celebrates New Advances in Wound Care Plus 30 Years of Safetac® Technology at WOCNext 2019
Mölnlycke Celebrates New Advances in Wound Care Plus 30 Years of Safetac® Technology at WOCNext 2019

M?lnlycke® will celebrate the game-changing invention of Safetac® technology while focusing on continued innovations in wound care at WOCNext 2019 being held June 23-26 in Nashville, TN.

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update
Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced...

Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

SOURCE Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y. and PARIS, June 21, 2019 /PRNewswire/ --  REGN3500 monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monot...

Women's Excellence Offers New Communications Methods for Patient Convenience
Women's Excellence Offers New Communications Methods for Patient Convenience

Women's Excellence offers new communication methods to make the overall patient experience and customer service more convenient.

Tampa General Hospital leases space in new USF Health Morsani College of Medicine building in downtown Tampa, offering stronger ties to help advance academics, patient care and research
Tampa General Hospital leases space in new USF Health Morsani College of Medicine building in downtown Tampa, offering stronger ties to help advance academics, patient care and research

Tampa General Hospital is leasing up to 25,000 square feet of space in the new USF Health Morsani College of Medicine and Heart Institute building now nearing completion in downtown Tampa, creating even more synergy with...

Pharmacy Technician Certification Board (PTCB) Awards Grants for Medication Safety Projects To Four State Pharmacy Associations
Pharmacy Technician Certification Board (PTCB) Awards Grants for Medication Safety Projects To Four State Pharmacy Associations

The Pharmacy Technician Certification Board (PTCB) has awarded grants to four state pharmacy associations in Connecticut, Iowa, North Dakota, and Tennessee to support projects that promote medication safety and advance the...

The Karis Group Promotes Kim Evans to President & CEO
The Karis Group Promotes Kim Evans to President & CEO

The Karis Group, an award-winning medical cost containment company in Austin, TX, announced today the promotion of Kim Evans to President & Chief Executive Officer. The Karis Group is pleased to have an experienced...

Statement from Acting FDA Commissioner Ned Sharpless, M.D. and Douglas Throckmorton, M.D., deputy center director for regulatory programs in FDA's Center for Drug Evaluation and Research, on the agency's benefit-risk framework for evaluating opioid analge
Statement from Acting FDA Commissioner Ned Sharpless, M.D. and Douglas Throckmorton, M.D., deputy center director for regulatory programs in FDA's Center for Drug Evaluation and Research, on the agency's benefit-risk framework for evaluating opioid analge

Addressing the crisis of opioid addiction is an issue of great concern for our nation and remains a top public health priority for the FDA. The agency continues to take new steps to confront this crisis, while also paying...

Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109

-Long Acting MDNA109 provides durable tumor control and strong memory response without further treatment when combined with checkpoint inhibitors

EyecareLive Unveils Enhanced Responsible Telemedicine Platform for Optometry and Ophthalmology
EyecareLive Unveils Enhanced Responsible Telemedicine Platform for Optometry and Ophthalmology

Today EyecareLive announced the release of their latest update - EyecareLive 2.0. EyecareLive was built by doctors, for doctors, with a mission to strengthen the doctor-patient relationship by providing a comprehensive...

Axiom Bank Donates $200,000 to Emory University
Axiom Bank Donates $200,000 to Emory University

Axiom Bank, N.A., a leading community bank headquartered in Central Florida, has donated $200,000 to the Emory Brain Health Center. This gift will help fund further research aimed at developing new treatments for brain...

Konica Minolta Healthcare, Novo Nordisk, Philips and Stryker join Emory Healthcare Innovation Hub with Sharecare to improve health care for all
Konica Minolta Healthcare, Novo Nordisk, Philips and Stryker join Emory Healthcare Innovation Hub with Sharecare to improve health care for all

The Emory Healthcare Innovation Hub today announced Konica Minolta Healthcare, Novo Nordisk, Philips and Stryker as its newest strategic partners committed to improving the patient care and provider experience by using...

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid...

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with...

Worklete Achieves 100% Year over Year Growth; Strengthens Team with Key Executive Hires
Worklete Achieves 100% Year over Year Growth; Strengthens Team with Key Executive Hires

Worklete, a technology platform that prevents musculoskeletal injuries in labor intensive workforces, announced today that it has achieved 100% year-over-year growth, having doubled its customer base in the shipping,...

Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer

Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and...

Rhode Island Headlines 

Massachusetts Headlines 

Entertainment